Press Releases

Date Title and Summary Additional Formats
Toggle Summary First Patient Enrolled In Phase 2 "Plasma" Trial with A-002 For Patients with Coronary Atherosclerosis View HTML
Toggle Summary Anthera Pharmaceuticals, Inc. Announces Appointment of Dr. James Pennington as Executive Vice President & Chief Medical Officer View HTML
Toggle Summary Anthera Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board for Respiratory and Acute Care Programs View HTML
Toggle Summary Anthera pharmaceuticals' Inc. announces formation of clinical advisory board for cardiovascular program View HTML
Toggle Summary Dr. David D. Waters Joins Anthera Pharmaceuticals As Cardiovascular Research Fellow View HTML
Toggle Summary Anthera Receives IND Approval from FDA to begin phase 2 "IMPACTS" trial with A-001 for prevention of acute chest syndrome in patients with sickle cell disease View HTML
Toggle Summary Anthera Receives FDA Approval to begin phase 2 "PLASMA" trial with A-002 For patients with coronary atherosclerosis View HTML
Toggle Summary Anthera Employee Keiko Mitsunobu Finishes Honolulu Marathon In Successful Effort To Raise Money For Children's Hospital Oakland Research Institute View HTML
Toggle Summary Anthera Pharmaceuticals Secures $36M Venture Financing To Initiate Clinical Programs View HTML
Toggle Summary Anthera Licenses Portfolio of Anti-Inflammatory Products From Eli Lilly and Company and Shionogi & Co., Ltd. View HTML